The DOI matches its Crossref record; 39 of the 40 references it cites were found in a registry or an index.
Downstaging Outcomes for Hepatocellular Carcinoma: Results From the Multicenter Evaluation of Reduction in Tumor Size before Liver Transplantation (MERITS-LT) Consortium
Open accessAbstract
Background & aims United Network of Organ Sharing (UNOS) has adopted uniform criteria for downstaging (UNOS-DS) of hepatocellular carcinoma (HCC) before liver transplantation (LT), but the downstaging success rate and intention-to-treat outcomes across broad geographic regions are unknown.Methods In this first multiregional study (7 centers, 4 UNOS regions), 209 consecutive patients with HCC undergoing downstaging based on UNOS-DS criteria were prospectively evaluated from 2016 to 2019.Results Probability of successful downstaging to Milan criteria and dropout at 2 years from the initial downstaging procedure was 87.7% and 37.3%, respectively. Pretreatment with lectin-reactive α-fetoprotein ≥10% (hazard ratio, 3.7; P = .02) was associated with increased dropout risk. When chemoembolization (n = 132) and yttrium-90 radioembolization (n = 62) were compared as the initial downstaging treatment, there were no differences in Modified Response Evaluation Criteria In Solid Tumors response, probability of or time to successful downstaging, waiting list dropout, or LT. Probability of LT at 3 years was 46.6% after a median of 17.2 months. In the explant, 17.5% had vascular invasion, and 42.8% exceeded Milan criteria (understaging). The only factor associated with understaging was the sum of the number of lesions plus largest tumor diameter on the last pre-LT imaging, and the odds of understaging increased by 35% per 1-unit increase in this sum. Post-LT survival at 2 years was 95%, and HCC recurrence occurred in 7.9%.Conclusion In this first prospective multiregional study based on UNOS-DS criteria, we observed a successful downstaging rate of >80% and similar efficacy of chemoembolization and yttrium-90 radioembolization as the initial downstaging treatment. A high rate of tumor understaging was observed despite excellent 2-year post-LT survival of 95%. Additional LRT to reduce viable tumor burden may reduce tumor understaging.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“In patients with successful downstaging, which indirectly reflects more-favourable tumour biology, transplantation can be considered145,146.”
From Adjuvant and neoadjuvant immunotherapies in hepatocellular carcinoma (2024) · cites this paper as [145]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Erdogan, D., Heijnen, B. H. M., Bennink, R. J., Kok, M., Dinant, S., Straatsburg, I. H., Gouma, D. J., & van Gulik, T. M. (2004) · Liver International · doi:10.1111/j.1478-3231.2004.00901.x · Cited by 11,656
Mazzaferro, V., Regalia, E., Doci, R., Andreola, S. A., Pulvirenti, A., Bozzetti, F., Montalto, F., Ammatuna, M., Morabito, A., & Gennari, L. (1996) · New England Journal of Medicine · doi:10.1056/nejm199603143341104 · Cited by 7,173
Acute Abdomen: A Rare Case of Ruptured Hepatocellular Carcinoma
Gloor, S., Jensen, K. O., Breitenstein, S., Binkert, C. A., Angst, E., & Hetzer, F. H. (2017) · Case Reports in Gastroenterology · doi:10.1159/000463378 · Cited by 5,370
Modified RECIST (mRECIST) Assessment for Hepatocellular Carcinoma
Lencioni, R. A., & Llovet, J. M. (2010) · Seminars in Liver Disease · doi:10.1055/s-0030-1247132 · Cited by 4,354
Primary carcinoma of the liver.A study of 100 cases among 48,900 necropsies
Edmondson, H. A., & Steiner, P. E. (1954) · Cancer · doi:10.1002/1097-0142(195405)7:3 · Cited by 2,789
Clavien, P., Lesurtel, M., Bossuyt, P. M., Gores, G. J., Langer, B., & Perrier, A. (2011) · The Lancet Oncology · doi:10.1016/s1470-2045(11)70175-9 · Cited by 1,022
Salem, R., Gordon, A. C., Mouli, S. K., Hickey, R., Kallini, J. R., Gabr, A., Mulcahy, M. F., Baker, T., Abecassis, M. M., Miller, F. H., et al. (2016) · Gastroenterology · doi:10.1053/j.gastro.2016.08.029 · Cited by 696
Yao, F. Y., Mehta, N. J., Flemming, J. A., Dodge, J. L., Hameed, B., Fix, O. K., Hirose, R., Fidelman, N. A., Kerlan, R. K., & Roberts, J. P. (2015) · Hepatology · doi:10.1002/hep.27752 · Cited by 485
Self-citationMitchell, D. G., Bruix, J., Sherman, M., & Sirlin, C. B. (2014) · Hepatology · doi:10.1002/hep.27304 · Cited by 483
Liver transplantation for hepatocellular carcinoma: outcomes and novel surgical approaches
Sapisochín, G., & Bruix, J. (2017) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2016.193 · Cited by 446
Research works printed but not linked: 1
- Yao, 2016, Reassessing the boundaries of liver transplantation for hepatocellular carcinoma: where do we stand with tumor down-staging?, Hepatology, 63, 1014
Cited by
Sorted by citations
AASLD Practice Guidance on prevention, diagnosis, and treatment of hepatocellular carcinoma
Singal, A. G., Llovet, J. M., Yarchoan, M., Mehta, N., Heimbach, J. K., Dawson, L. A., Jou, J. H., Kulik, L. M., Agopian, V. G., Marrero, J. A., et al. (2023) · Hepatology · doi:10.1097/hep.0000000000000466 · Cited by 2,052
“[240] Attempts to downstage with a goal of transplantation must be weighted with the probability of success using locoregional therapy.”
InfluentialSelf-citationSingal, A. G., Kanwal, F., & Llovet, J. M. (2023) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-023-00825-3 · Cited by 1,029
EASL Clinical Practice Guidelines on the management of hepatocellular carcinoma
Sangro, B., Argemi, J., Ronot, M., Paradis, V., Meyer, T., Mazzaferro, V., Jepsen, P., Golfieri, R., Galle, P., Dawson, L., et al. (2025) · Journal of Hepatology · doi:10.1016/j.jhep.2024.08.028 · Cited by 985
Ganesan, P., & Kulik, L. (2022) · Clinics in Liver Disease · doi:10.1016/j.cld.2022.08.004 · Cited by 489
Adjuvant and neoadjuvant immunotherapies in hepatocellular carcinoma
Llovet, J. M., Pinyol, R., Yarchoan, M., Singal, A. G., Marron, T. U., Schwartz, M., Pikarsky, E., Kudo, M., & Finn, R. S. (2024) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-024-00868-0 · Cited by 391
2022 KLCA-NCC Korea practice guidelines for the management of hepatocellular carcinoma
Korean Liver Cancer Association (KLCA), & National Cancer Center (NCC) Korea (2022) · Clinical and Molecular Hepatology · doi:10.3350/cmh.2022.0294 · Cited by 364
Hepatocellular carcinoma: updates on epidemiology, surveillance, diagnosis and treatment
Hwang, S. Y., Danpanichkul, P., Agopian, V. G., Mehta, N., Parikh, N. D., Abou‐Alfa, G. K., Singal, A. G., & Yang, J. D. (2024) · Clinical and Molecular Hepatology · doi:10.3350/cmh.2024.0824 · Cited by 359
Self-citationBCLC strategy for prognosis prediction and treatment recommendations: The 2026 update
Reig, M., Sanduzzi‐Zamparelli, M., Forner, A., Rimola, J., Ferrer, J., Burrel, M., García‐Criado, Á., Díaz, A., Llarch, N., Iserte, G., et al. (2025) · Journal of Hepatology · doi:10.1016/j.jhep.2025.10.020 · Cited by 253
Breakthroughs in Hepatocellular Carcinoma Therapies
Singal, A. G., Kudo, M., & Bruix, J. (2023) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2023.01.039 · Cited by 167
Ten-Year Outcomes of Liver Transplant and Downstaging for Hepatocellular Carcinoma
Tabrizian, P., Holzner, M. L., Mehta, N. J., Halazun, K. J., Agopian, V. G., Yao, F. Y., Busuttil, R. W., Roberts, J. P., Emond, J. C., Samstein, B., et al. (2022) · JAMA Surgery · doi:10.1001/jamasurg.2022.2800 · Cited by 157
Self-citation2022 KLCA-NCC Korea Practice Guidelines for the Management of Hepatocellular Carcinoma
(2022) · Korean Journal of Radiology · doi:10.3348/kjr.2022.0822 · Cited by 143
2022 KLCA-NCC Korea practice guidelines for the management of hepatocellular carcinoma
(2022) · Journal of Liver Cancer · doi:10.17998/jlc.2022.11.07 · Cited by 145
Kinsey, E. N., & Lee, H. M. (2024) · Cancers · doi:10.3390/cancers16030666 · Cited by 145
Tabrizian, P., Holzner, M. L., Ajmera, V. H., Kim, A. K., Zhou, K., Schnickel, G. T., Torosian, K., Hoteit, M. A., Marino, R., Li, M., et al. (2024) · Journal of Hepatology · doi:10.1016/j.jhep.2024.09.003 · Cited by 96
Self-citationImmunotherapy and transplantation for hepatocellular carcinoma
Tabrizian, P., Abdelrahim, M., & Schwartz, M. (2024) · Journal of Hepatology · doi:10.1016/j.jhep.2024.01.011 · Cited by 95
Self-citationTan, D. J. H., Lim, W. H., Yong, J. N., Ng, C. H., Muthiah, M. D., Tan, E. X. X., Xiao, J., Lin, S. Y., Tang, A. S. P., Pan, X. H., et al. (2022) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2022.02.018 · Cited by 84
Tran, N. H., Muñoz, S., Thompson, S. M., Hallemeier, C. L., & Bruix, J. (2022) · Hepatology · doi:10.1002/hep.32613 · Cited by 76
Li, M., Bhoori, S., Mehta, N. J., & Mazzaferro, V. (2024) · Journal of Hepatology · doi:10.1016/j.jhep.2024.05.037 · Cited by 70
Self-citationZhou, J., Sun, H., Wang, Z., Cong, W., Zeng, M., Zhou, W., Liu, L., Wen, T., Kuang, M., Zhang, B., et al. (2025) · Liver Cancer · doi:10.1159/000546574 · Cited by 78
Guo, Z., Liu, Y., Ling, Q., Xu, L., Wang, T., Zhu, J., Lin, Y., Lu, X., Qu, W., Zhang, F., et al. (2024) · American Journal of Transplantation · doi:10.1016/j.ajt.2024.04.007 · Cited by 68
Yilma, M., Xu, R. H., Saxena, V., Muzzin, M., Tucker, L.-Y. S., Lee, J. D., Mehta, N. J., & Mukhtar, N. A. (2024) · JAMA Network Open · doi:10.1001/jamanetworkopen.2024.35066 · Cited by 66
Self-citationLiver Transplantation for Hepatocellular Carcinoma: How Should We Improve the Thresholds?
Shimamura, T., Goto, R., Watanabe, M., Kawamura, N., & Takada, Y. (2022) · Cancers · doi:10.3390/cancers14020419 · Cited by 52
Locoregional Treatments for Bridging and Downstaging HCC to Liver Transplantation
Crocetti, L., Bozzi, E., Scalise, P., Bargellini, I., Lorenzoni, G., Ghinolfi, D., Campani, D., Balzano, E., SIMONE, P. D., & Cioni, R. (2021) · Cancers · doi:10.3390/cancers13215558 · Cited by 48
Kim, D.-S., Yoon, Y.-I., Kim, B. K., Choudhury, A., Kulkarni, A., Park, J. Y., Kim, J., Sinn, D. H., Joo, D. J., Choi, Y., et al. (2024) · Hepatology International · doi:10.1007/s12072-023-10629-3 · Cited by 47
Olumba, F. C., Zhou, F., Park, Y., Chapman, W. C., & RESTORE Investigators Group (2023) · Journal of the American College of Surgeons · doi:10.1097/xcs.0000000000000555 · Cited by 41
Claasen, M. P. A. W., Sneiders, D., Rakké, Y. S., Adam, R. A., Bhoori, S., Cillo, U., Fondevila, C., Reig, M., Sapisochín, G., Tabrizian, P., et al. (2023) · Transplant International · doi:10.3389/ti.2023.11648 · Cited by 41
Self-citationChouik, Y., Erard, D., Demian, H., Schulz, T. F., Mazard, T., Hartig-Lavie, K., Antonini, T., Mabrut, J., Mohkam, K., Rode, A., et al. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1205997 · Cited by 35
Mehta, N. J., Kotwani, P., Norman, J. S., Shui, A., Li, P. J., Saxena, V., Chan, W., & Yao, F. Y. (2023) · Liver Transplantation · doi:10.1097/lvt.0000000000000149 · Cited by 34
Self-citationLv, Z., Xiang, X., Yong, J., Zhou, Y., Wu, Y., Li, L., Wang, Y., Zhang, Z., Xia, Q., & Feng, H. (2024) · International Journal of Surgery · doi:10.1097/js9.0000000000001813 · Cited by 33
Emerging curative-intent minimally-invasive therapies for hepatocellular carcinoma
Zane, K. E., Nagib, P. B., Jalil, S., Mumtaz, K., & Makary, M. S. (2022) · World Journal of Hepatology · doi:10.4254/wjh.v14.i5.885 · Cited by 32
Intraarterial Therapies for the Management of Hepatocellular Carcinoma
Garg, T., Shrigiriwar, A. P., Habibollahi, P., Cristescu, M. M., Liddell, R. P., Chapiro, J., Inglis, P., Camacho, J. C., & Nezami, N. (2022) · Cancers · doi:10.3390/cancers14143351 · Cited by 28
Magyar, C. T. J., O'Kane, G. M., Aceituno, L., Li, Z., Vogel, A., Bruix, J., Mazzaferro, V., & Sapisochín, G. (2024) · Journal of Clinical Oncology · doi:10.1200/jco.24.00857 · Cited by 27
Natarajan, B., Tabrizian, P., Hoteit, M. A., Frenette, C. T., Parikh, N. D., Ghaziani, T., Dhanasekaran, R., Guy, J. E., Shui, A. M., Florman, S. S., et al. (2023) · American Journal of Transplantation · doi:10.1016/j.ajt.2023.07.021 · Cited by 26
Self-citationXu, E., Tabrizian, P., Gutierrez, J., Hoteit, M. A., Ghaziani, T., Zhou, K., Parikh, N. D., Ajmera, V. H., Aby, E. S., Shui, A., et al. (2025) · Hepatology · doi:10.1097/hep.0000000000001231 · Cited by 25
Self-citationNeoadjuvant atezolizumab plus bevacizumab prior liver transplantation for hepatocellular carcinoma
Tabrizian, P., Marino, R., Bhoori, S., Zeitlhoefler, M., Mehta, N. J., Banz, V. M., Gruttadauria, S., Iavarone, M. A., Mazzarelli, C., Simonotti, N., et al. (2024) · JHEP Reports · doi:10.1016/j.jhepr.2024.101246 · Cited by 24
Self-citationLópez‐López, V., Miura, K., Kuemmerli, C., Capel, A., Eshmuminov, D., Ferreras, D., Baroja‐Mazo, A., Cascales-Campos, P. A., Jiménez-Mascuñán, M. I., Pons, J. A., et al. (2023) · Cancers · doi:10.3390/cancers15072122 · Cited by 24
Briody, H., Duong, D., Yeoh, S. W., Hodgson, R., Yong, T. L., Hannah, A., Lee, M. J., Leong, S., Maingard, J. T., Asadi, H., et al. (2023) · Journal of Vascular and Interventional Radiology · doi:10.1016/j.jvir.2023.03.020 · Cited by 22
Transplant oncology – Current indications and strategies to advance the field
Krendl, F. J., Bellotti, R., Sapisochín, G., Schaefer, B., Tilg, H., Scheidl, S. J., Margreiter, C., Schneeberger, S., Oberhuber, R., & Maglione, M. (2023) · JHEP Reports · doi:10.1016/j.jhepr.2023.100965 · Cited by 22
Modern therapeutic approaches for hepatic tumors: progress, limitations, and future directions
Sadrinasab, S., Saket, S., Pourmohammadi, N., Khosravi, F., & Fakhr, M. S. (2025) · Discover Oncology · doi:10.1007/s12672-025-02773-z · Cited by 22
Singal, A. G., Quirk, L., Boike, J. R., Chernyak, V., Feng, Z., Giamarqo, G., Kanwal, F., Ioannou, G. N., Manes, S., Marrero, J. A., et al. (2024) · Hepatology · doi:10.1097/hep.0000000000001203 · Cited by 20
Self-citationHuang, A. C., Dodge, J. L., Yao, F. Y., & Mehta, N. J. (2022) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2022.08.023 · Cited by 20
Self-citationIndication of Liver Transplant for HCC: Current Status and Future Directions
Horwitz, J. K., & Agopian, V. G. (2024) · Current Hepatology Reports · doi:10.1007/s11901-024-00641-y · Cited by 17
The Value of Clinical Decision Support in Healthcare: A Focus on Screening and Early Detection
Schäfer, H., Lajmi, N., Valente, P., Pedrioli, A., Cigoianu, D., Hoehne, B., Schenk, M., Guo, C., Singhrao, R., Gmuer, D., et al. (2025) · Diagnostics · doi:10.3390/diagnostics15050648 · Cited by 17
Gonvers, S., Tabrizian, P., Melloul, E., Dormond, O., Schwartz, M., Demartines, N., & Labgaa, I. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.940473 · Cited by 16
Self-citationDajti, G., Germinario, G., Prosperi, E., Siniscalchi, A., Vasuri, F., Valente, S., Odaldi, F., Maroni, L., Serenari, M., Bertuzzo, V. R., et al. (2024) · Artificial Organs · doi:10.1111/aor.14715 · Cited by 14
Lu, X., Zhu, Q., Cai, J., Yang, Z., Gu, G., Pang, L., Su, M., Zhang, F., Lin, H., Wu, W., et al. (2024) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-024-03853-9 · Cited by 13
Wagle, N. S., Park, S., Washburn, D. J., Ohsfeldt, R. L., Kum, H., & Singal, A. G. (2024) · Cancer Epidemiology Biomarkers & Prevention · doi:10.1158/1055-9965.epi-23-1236 · Cited by 12
Recent Advances in Liver Transplantation for Hepatocellular Carcinoma
Li, P. J., Shah, S., & Mehta, N. J. (2024) · Current Treatment Options in Oncology · doi:10.1007/s11864-024-01247-8 · Cited by 11
Self-citationLee, I., Wang, H.-W., Teng, W., Lin, T., Chen, C.-H., Lai, H., Lee, T., Chang, C.-W., Hung, C., Dai, C., et al. (2025) · Clinical and Molecular Hepatology · doi:10.3350/cmh.2025.0724 · Cited by 11
Mehta, N. J., Kelley, R. K., & Yao, F. Y. (2023) · Hepatology · doi:10.1097/hep.0000000000000452 · Cited by 11
Self-citationFung, J. J., di Sabato, D., Liao, C., Ahmed, O. S., & Pillai, A. A. (2022) · Hepatobiliary & pancreatic diseases international · doi:10.1016/j.hbpd.2022.09.003 · Cited by 11
Masior, Ł., Krasnodębski, M., Kuncewicz, M., Karaban, K., Jaszczyszyn, I., Kruk, E., Małecka‐Giełdowska, M., Korzeniowski, K., Figiel, W., Krawczyk, M., et al. (2023) · Cancers · doi:10.3390/cancers15153962 · Cited by 10
Wu, X. J., Kwong, A. J., Heller, M., Lokken, R. P., Fidelman, N. A., & Mehta, N. J. (2023) · Liver Transplantation · doi:10.1097/lvt.0000000000000249 · Cited by 10
Self-citationThe Role of AFP-L3 and DCP Biomarkers in the Diagnosis and Management of Hepatocellular Carcinoma
Norman, J. S., & Mehta, N. J. (2025) · Current Hepatology Reports · doi:10.1007/s11901-025-00686-7 · Cited by 10
Self-citationBraun, F., Schäfer, J. P., Dobbermann, H., Becker, T., & Linecker, M. (2022) · Die Chirurgie · doi:10.1007/s00104-022-01661-4 · Cited by 10
Upper Limits of Downstaging for Hepatocellular Carcinoma in Liver Transplantation
Biolato, M., Galasso, T., Marrone, G., Miele, L., & Grieco, A. (2021) · Cancers · doi:10.3390/cancers13246337 · Cited by 9
Multidisciplinary approaches to downstaging hepatocellular carcinoma: present and future
Hwang, S. Y., Choi, H., Jeon, W., & Kim, R. (2024) · Journal of Liver Cancer · doi:10.17998/jlc.2024.08.30 · Cited by 8
Xiao, T., Hu, S., Dong, S., Cai, Q., Gong, W., Zhang, Y., Long, C., & Li, X. (2024) · International Immunopharmacology · doi:10.1016/j.intimp.2024.112144 · Cited by 7
Bonne, L., Deroose, C. M., Verslype, C., Monbaliu, D. R. L., Dekervel, J., Laeken, C. V., Vandecaveye, V., Laenen, A., Pirenne, J., & Maleux, G. A. (2024) · Journal of Vascular and Interventional Radiology · doi:10.1016/j.jvir.2024.10.021 · Cited by 7
Singal, A. G., Agopian, V. G., Dawson, L. A., El-Khoueiry, A., Finn, R. S., Halazun, K., Heimbach, J. K., Kelley, R. K., Kim, E., Kulik, L., et al. (2026) · Hepatology · doi:10.1097/hep.0000000000001834 · Cited by 7
Self-citationPang, L., Xu, L.-B., & Wu, W. (2024) · Transplantation Proceedings · doi:10.1016/j.transproceed.2024.05.041 · Cited by 7
Kim, N. G., Yao, F. Y. K., Kwong, A. J., & Mehta, N. J. (2026) · Journal of Hepatology · doi:10.1016/j.jhep.2026.01.008 · Cited by 6
Self-citationMartin, S. P., Mehta, N. J., & Emamaullee, J. A. (2024) · Liver Transplantation · doi:10.1097/lvt.0000000000000350 · Cited by 6
Self-citationSon, S. Y., Geevarghese, R., Marinelli, B. S., Zhao, K., Covey, A. M., Maxwell, A. W. P., Wei, A. C.-C., Jarnagin, W. R., D'Angelica, M. I., & Yarmohammadi, H. (2024) · Cancers · doi:10.3390/cancers16173024 · Cited by 6
Wong, J. K., Lim, H. J., Tam, V. C., Burak, K. W., Dawson, L. A., Chaudhury, P. K., Abraham, R. J., Meyers, B. M., Sapisochín, G., Valenti, D. A., et al. (2023) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2023.102526 · Cited by 6
Cesario, S., Genovesi, V., Salani, F., Vasile, E., Fornaro, L., Vivaldi, C., & Masi, G. (2023) · Life · doi:10.3390/life13071562 · Cited by 6
From evidence to clinical practice: Bridging the gap of new liver cancer therapies in Latin America.
Piñero, F., Mauro, E., Casciato, P. C., & Forner, A. (2023) · Annals of Hepatology · doi:10.1016/j.aohep.2023.101185 · Cited by 6
Kolarich, A. R., Ishaque, T., Ruck, J. M., Solomon, A. J., Massie, A. B., Segev, D. L., Gurakar, A. O., Cameron, A. M., Georgiades, C. S., Hong, K. K., et al. (2022) · Journal of Vascular and Interventional Radiology · doi:10.1016/j.jvir.2022.06.016 · Cited by 5
Wang, S., Sun, K., Jin, S., Wang, K., Jiang, N., Shan, S., Lü, Q., Lv, G., & Dong, J. (2023) · BMC Cancer · doi:10.1186/s12885-023-11386-0 · Cited by 5
Xie, M., & Zhen, Y. (2026) · CardioVascular and Interventional Radiology · doi:10.1007/s00270-026-04379-6 · Cited by 4
The rise of transplant oncology in primary liver cancer and metastatic disease
Wassmer, C., Gelli, M., Wong, T. C.-L., Li, Z., Zorigtbaatar, A., Marino, R., Aceituno, L., Adam, R. A., Chan, A. C. Y., Heimbach, J. K., et al. (2026) · Hepatology · doi:10.1097/hep.0000000000001723 · Cited by 4
Self-citationHund, H. C., Du, L., Matsuoka, L. K., Sze, D. Y., Kennedy, A. S., Golzarian, J., Gandhi, R. T., Collins, Z. S., & Brown, D. B. (2023) · Journal of Vascular and Interventional Radiology · doi:10.1016/j.jvir.2023.08.039 · Cited by 4
Liver Transplantation for Hepatocellular Carcinoma: A Narrative Review and A Glimpse into The Future
Liu, H., Sethi, V., Li, X., Xiao, Y., & Humar, A. (2024) · Seminars in Liver Disease · doi:10.1055/a-2242-7543 · Cited by 4
Updates in liver transplantation policy for patients with hepatocellular carcinoma (HCC)
Mehta, N. J. (2024) · Clinical Liver Disease · doi:10.1097/cld.0000000000000157 · Cited by 4
Self-citationBurgos, M. M., Grande, R. G., Ortega, S. L., Leiva, I. S., Lombardo, J. D. L. C., Santoyo, J. S., & Pérez, M. J. (2024) · Biomedicines · doi:10.3390/biomedicines12061302 · Cited by 4
SBRT for bridging and downstaging HCC before transplant
Li, Z., Yan, M., Claasen, M. P. A. W., Rajendran, L., Magyar, C. T. J., Saha, S., Lee, C., Selzner, N., Jaeckel, E., Ghanekar, A., et al. (2025) · JHEP Reports · doi:10.1016/j.jhepr.2025.101451 · Cited by 4
Management of hepatocellular carcinoma prior to liver transplantation: latest developments
Robert, A., Hunold, T. M., & Parikh, N. D. (2025) · Hepatic Oncology · doi:10.1080/20450923.2025.2549676 · Cited by 4
Self-citationPushing the limits of treatment for hepatocellular carcinoma
Jones-Pauley, M., Victor, D. W., & Kodali, S. (2023) · Current Opinion in Organ Transplantation · doi:10.1097/mot.0000000000001123 · Cited by 4
Wong, R. J., Jayasekera, C. R., Jones, P. D., Kanwal, F., Singal, A. G., Ahmed, A., Taglienti, R., Younossi, Z. M., Kulik, L., & Mehta, N. J. (2022) · Gastroenterology Research · doi:10.14740/gr1573 · Cited by 4
Self-citationMehta, N. J., & Yao, F. Y. (2021) · Liver Transplantation · doi:10.1002/lt.26302 · Cited by 4
Self-citationAmara, D., Melehy, A., Ebaid, S. S., Kaldas, F. M., Farmer, D. G., Stock, P. G., Bui, A. A. T., Mehta, N. J., & Agopian, V. G. (2025) · Clinical Transplantation · doi:10.1111/ctr.70254 · Cited by 3
Self-citationFakhoury, B., Jahagirdar, V., Alsaqa, M., Sierra, L., Razzak, I. A., Parraga, X., Khalid, M., Bonder, A., Vinayek, R., & Saberi, B. (2025) · Liver Transplantation · doi:10.1097/lvt.0000000000000743 · Cited by 3
Hepatocellular carcinoma and liver transplant: What about neo- and adjuvant immunotherapy
Khalaf, M. H., Tran, B. V., Krendl, F. J., Doan, T., Rachko, J., Marino, R., & Tabrizian, P. (2025) · Hepatobiliary & pancreatic diseases international · doi:10.1016/j.hbpd.2025.10.004 · Cited by 3
Self-citationZavareh, M. S. R., & Yang, J. D. (2026) · Gastroenterology report · doi:10.1093/gastro/goag018 · Cited by 3
Hepatocellular Carcinoma Bridging and Downstaging: Advances in Locoregional Therapy
Fite, E. L., Sekar, N., Venancius, J., & Makary, M. S. (2026) · Biomedicines · doi:10.3390/biomedicines14040877 · Cited by 3
Yan, H., Xiang, Z., Zhao, C., Zou, S., & Huang, M. (2022) · Journal of Vascular and Interventional Radiology · doi:10.1016/j.jvir.2022.12.466 · Cited by 3
Arterial Complications in Patients Undergoing Liver Transplantation After Previous TACE Treatment
Weiße, S., Mostafa, K., Andersson, J., Gundlach, J.-P., Becker, T., Schäfer, J. P., & Braun, F. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14041262 · Cited by 3
Varma, V., Nekarakanti, P. K., Agarwal, S. K., Dey, R., & Gupta, S. C. (2024) · Journal of Clinical and Experimental Hepatology · doi:10.1016/j.jceh.2024.102490 · Cited by 3
Optimal Liver Transplantation Criteria for Hepatocellular Carcinoma
Yilma, M., & Mehta, N. J. (2023) · Surgical Oncology Clinics of North America · doi:10.1016/j.soc.2023.06.011 · Cited by 3
Self-citationSha, M., Cao, J., & Xia, Q. (2023) · Journal of Hepatology · doi:10.1016/j.jhep.2023.09.034 · Cited by 3
Gurley, T., Hernáez, R., Cerda, V., Thomas, T., Narasimman, M., Mittal, S., Al-Hasan, M., Daher, D., & Singal, A. G. (2025) · EClinicalMedicine · doi:10.1016/j.eclinm.2025.103113 · Cited by 2
Anders, M. M., de Mattos, Â. Z., Debes, J. D., Beltrán, O., Coste, P., Marín, J. I., Chagas, A. L., Menéndez, J., Estupiñán, E. C., Ferrer, J. D., et al. (2025) · Annals of Hepatology · doi:10.1016/j.aohep.2025.101905 · Cited by 2
Yu, D., Chen, H., & Wang, L. (2025) · Cancer Reports · doi:10.1002/cnr2.70244 · Cited by 2
Kulkarni, A. V., Singal, A. G., & Reddy, K. R. (2025) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.70333 · Cited by 2
Kim, S. H. (2025) · Cancers · doi:10.3390/cancers17223671 · Cited by 2
Zorigtbaatar, A., Moral, K., Sapisochín, G., Kabaçam, G., Selzner, N., Tabrizian, P., & Marino, R. (2026) · International Journal of Surgery · doi:10.1097/js9.0000000000004958 · Cited by 2
Self-citationAgrawal, D., Jothimani, D. K., Bhoori, S., Reddy, G. N., Saigal, S., Rela, M., & Mazzaferro, V. (2026) · Hepatology International · doi:10.1007/s12072-026-11097-1 · Cited by 2
Selim, M. A., Hohenwalter, E. J., Rilling, W. S., & Hong, J. C. (2023) · Transplantation Proceedings · doi:10.1016/j.transproceed.2023.03.084 · Cited by 2
Huo, H., Wang, X., Xu, S., Niu, X., Cheng, L., Yuan, Z., Huo, S., & Fang, P. (2023) · Oncology Letters · doi:10.3892/ol.2023.14052 · Cited by 2
de Morais, B. G., Horbe, A. F., Coral, G. P., Jotz, R. D. F., Fontana, P. C., & de Mattos, Â. A. (2024) · European Journal of Gastroenterology & Hepatology · doi:10.1097/meg.0000000000002869 · Cited by 2
Metadata
- Authors
- Mehta, N., Frenette, C., Tabrizian, P., Hoteit, M., Guy, J., Parikh, N., Ghaziani, T. T., Dhanasekaran, R., Dodge, J. L., Natarajan, B., Holzner, M. L., Frankul, L., Chan, W., Fobar, A., Florman, S., & Yao, F. Y.
- Affiliations
- University of California, San Francisco (US)
- Scripps Green Hospital (US)
- Icahn School of Medicine at Mount Sinai (US)
- University of Pennsylvania (US)
- California Pacific Medical Center (US)
- University of Michigan (US)
- Stanford University (US)
- Corresponding author
- Mehta, Neil
- ORCID
- Venue
- Gastroenterology
- Publisher
- Elsevier BV
- Published
- 2021-11
- Volume
- 161
- Issue
- 5
- Pages
- 1502-1512
- ISSN
- 0016-5085 (ISSN-L)
- PMC
- PMC8545832
- OpenAlex
- W3184850586
- Cited by
- 154
- References
- 40
- Citations by year
- 2026: 25 · 2025: 29 · 2024: 42 · 2023: 33 · 2022: 20 · 2021: 3
- FWCI
- 13.61
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Gastroenterology (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- eScholarship (California Digital Library) (submittedVersion)
- Funders
- Exelixis
- National Institute of Diabetes and Digestive and Kidney Diseases
- Liver Center, University of California, San Francisco
- Eli Lilly and Company
- Bayer Fund
- Eisai
- National Institutes of Health (P30 DK026743)
- Genentech
- Topics
- Health Sciences › Medicine › Hepatology › Hepatocellular Carcinoma Treatment and Prognosis
- Health Sciences › Medicine › Surgery › Organ Transplantation Techniques and Outcomes
- Health Sciences › Medicine › Oncology › Renal cell carcinoma treatment
- Keywords
- hepatocellular carcinoma, tumor downstaging, liver transplantation, Milan criteria, understaging, transarterial chemoembolization, yttrium-90 radioembolization, alpha-fetoprotein, tumor size, HCC recurrence, post-transplant survival, vascular invasion
- MeSH terms
- Aged, Feasibility Studies, Female, Carcinoma, Hepatocellular, Humans, Liver Neoplasms, Male, Middle Aged, Neoplasm Recurrence, Local, Neoplasm Staging, Patient Dropouts, Prospective Studies, Risk Factors, Time Factors, United States, Waiting Lists, Liver Transplantation, Chemoembolization, Therapeutic, Treatment Outcome, Disease Progression, Risk Assessment, Radiopharmaceuticals, Tumor Burden
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
